The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Vuuren, A. J.
Right arrow Articles by Thepen, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Vuuren, A. J.
Right arrow Articles by Thepen, T.
The Journal of Immunology, 2006, 176: 5833-5838.
Copyright © 2006 by The American Association of Immunologists

CD64-Directed Immunotoxin Inhibits Arthritis in a Novel CD64 Transgenic Rat Model1

Anneke J. van Vuuren2,*, Joel A. G. van Roon*,{dagger}, Vanessa Walraven*, Ilonka Stuij*, Martin C. Harmsen{ddagger}, Pamela M. J. McLaughlin{ddagger}, Jan G. J. van de Winkel*,§ and Theo Thepen*,||

* Department of Immunology, Immunotherapy Laboratory, University Medical Center, Utrecht, The Netherlands; {dagger} Department of Rheumatology and Clinical Immunology, University Medical Center, Utrecht, The Netherlands; {ddagger} Department of Pathology and Laboratory Medicine, University of Groningen, Groningen, The Netherlands; § Genmab, Utrecht, The Netherlands; Medarex, Annandale, NJ 08801; and || Department of Pharmaceutical Product Development, Fraunhofer Institut fur Molekular und angewandte Ockologie, Aachen, Germany

Macrophages are known to play a key role during inflammation in rheumatoid arthritis (RA). Inflammatory macrophages have increased expression of CD64, the high-affinity receptor for IgG. Targeting this receptor through a CD64-directed immunotoxin, composed of an Ab against CD64 and Ricin A, results in effective killing of inflammatory macrophages. In this study, we show elevated levels of CD64 on synovial macrophages in both synovial lining and synovial fluid in RA patients. The CD64-directed immunotoxin efficiently eliminates activated synovial macrophages in vitro, while leaving quiescent, low CD64-expressing macrophages unaffected. To examine whether killing of CD64 macrophages results in therapeutic effects in vivo, we established an adjuvant arthritis (AA) model in newly generated human CD64 (hCD64) transgenic rats. We demonstrate that hCD64 regulation in this transgenic rat model is similar as in humans. After AA induction, treatment with CD64-directed immunotoxin results in significant inhibition of disease activity. There is a direct correlation between immunotoxin treatment and decreased macrophage numbers, followed by diminished inflammation and bone erosion in paws of these hCD64 transgenic rats. These data support synovial macrophages to play a crucial role in joint inflammation in AA in rats and in human RA. Selective elimination of inflammatory macrophages through a CD64-directed immunotoxin may provide a novel approach for treatment of RA.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
B. Stahnke, T. Thepen, M. Stocker, R. Rosinke, E. Jost, R. Fischer, M. K. Tur, and S. Barth
Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes
Mol. Cancer Ther., September 1, 2008; 7(9): 2924 - 2932.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.